Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | TET3 | O43151 | 1/20 | 0.38 |
| ▸ | FBXL19 | Q6PCT2 | 1/20 | 0.38 |
| ▸ | CXXC5 | Q7LFL8 | 1/20 | 0.38 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.38 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.38 |
| ▸ | CXXC4 | Q9H2H0 | 1/20 | 0.38 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL373567 | 0.82 | AKR1C1 (0.68) | OPRM1KMT2AAKR1C1CYP2C19HDAC1 | |
| Hydrochloric Acid SCHEMBL2552731 | 0.81 | AKR1C1 (0.66) | OPRM1KMT2AAKR1C1HDAC1TET3 | |
| Ammonia Solution, Strong SCHEMBL3210975 | 0.81 | AKR1C1 (0.66) | OPRM1KMT2AAKR1C1CYP2C19HDAC1 | |
| Hydrochloric Acid SCHEMBL18281540 | 0.81 | AKR1C1 (0.66) | OPRM1KMT2AAKR1C1HDAC1TET3 | |
| SCHEMBL378736 | 0.77 | CYP2C19 (0.63) | OPRM1KMT2AAKR1C1CYP2C19MEN1 | |
| SCHEMBL974744 | 0.75 | OPRM1 (0.59) | OPRM1KMT2ACYP2C19MEN1HDAC1 | |
| SCHEMBL378799 | 0.75 | OPRM1 (0.70) | OPRM1KMT2AMEN1HDAC1 | |
| SCHEMBL3565382 | 0.75 | OPRM1 (0.51) | OPRM1KMT2AAKR1C1CYP2C19MEN1 | |
| SCHEMBL16058193 | 0.74 | KMT2A (0.57) | OPRM1KMT2AAKR1C1CYP2C19MEN1 | |
| Hydrochloric Acid SCHEMBL2636222 | 0.74 | OPRM1 (0.68) | OPRM1KMT2AMEN1HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1549646-A4 | PIPERIDINE DERIVATIVES | AMGEN INC (US) | 2008-05-21 | — | — | EP | disclosed |
| EP-1549646-A2 | PIPERIDINE DERIVATIVES | Tularik Inc. (US) | 2005-07-06 | — | — | EP | disclosed |
| US-20040142956-A1 | Piperidine derivatives | AMGEN INC. | 2004-07-22 | — | — | US | disclosed |
| WO-2004028459-A2 | PIPERIDINE DERIVATIVES | TULARIK INC. (US) | 2004-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142956-A1 | Piperidine derivatives | VIPR2, VIPR1, GRPR | OPRM1 163/4885KMT2A 3038/4885AKR1C1 1960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.